Monitoring Agency Report reveals fund utilization deviations for preferential issue in Q2FY26
Monitoring agency report for Ind-Swift Laboratories reveals ₹45.21 crore reimbursement deviation and ₹64.09 crore investment in a third-party NBFC from preferential issue funds.
The identified deviations, particularly the 14.37% deviation from stated objects and the investment in an NBFC, could have a high impact on investor confidence and regulatory scrutiny regarding the company's corporate governance and fund management practices.
The report indicates significant deviations in the utilization of preferential issue funds, including unapproved reimbursements and investment in a third-party NBFC, which raises concerns about compliance and transparency.
Ind-Swift Laboratories Limited has submitted the Monitoring Agency Report for the quarter ended September 30, 2025, concerning the utilization of funds raised through a preferential issue of ₹314.60 crore. CARE Ratings Limited, the Monitoring Agency, reported several deviations: * A claim for reimbursement of ₹45.21 crore for business expansion related to the previous quarter was not allowed as per the preferential issue's objects. * ₹64.09 crore from the issue proceeds was invested in Khandelwal Finance Private Ltd. (KFPL), a third-party NBFC. * The Monitoring Agency noted that the company transferred a majority of funds from its monitoring account to multiple current/overdraft accounts, limiting the direct ascertainment of issue proceeds utilization. * Shareholder approval was not obtained for the ₹45.21 crore reimbursement, constituting a material deviation of 14.37% of the total issue amount.
The company's Board of Directors responded that the ₹45.21 crore reimbursement related to capital expenditure for a group company, Ind-Swift Limited, which merged with Ind-Swift Laboratories Limited on July 17, 2025 (effective August 8, 2025), making it an approved purpose. The investment in KFPL was in secured Optionally Convertible Redeemable Preference Shares at 8.25% for better returns from spare funds, with timely disclosure to stock exchanges. The company asserts that funds were utilized in accordance with the offer document, supported by management and CA certificates, despite the commingling of funds. The total unutilized amount at the end of the quarter was ₹0.46 crore.
What to do with a filing like this
Ind-Swift Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under preferential allotment. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ind-Swift Laboratories Limited. Read the original for the full detail.